ALMS

Alumis Inc. (ALMS) | Rumor.io

Alumis

ALMS

Attention (50-day avg)0%

Attention rank (50-day avg)#816

Bullish sentiment (50-day avg)29%

Price to earnings ratio0.17

Market capitalization926.8M

Earnings per share-4.11

Dividend yield (TTM)—

Revenue (annual)24.1M

Net income (annual)-243.3M

Social

What share of all stock conversation is about ALMS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0.01% +0	0% +0

Sep 10

Alumis Inc. ($ALMS) director Akkaraju Srinivas made a significant open-market purchase of 986,721 shares worth $10.73M at $10.87 per share.
The purchase is considered a bullish signal, indicating the director's confidence in the company's future.
Alumis Inc. is preparing to submit a New Drug Application (NDA) for envudeucitinib, a treatment for psoriasis, in Q4 2026, which could be a catalyst for the stock.

Generated by AI

Sentiment

Of the messages about ALMS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +91.16	23.6% -37.88	74.07% -4.11
Bearish	—	0% -91.16	76.4% +37.88	25.93% +4.11

Bullish· Sep 2

$ALMS is expected to reach a price target of $37, according to Oppenheimer, making it a "no brainer" investment.
The company's psoriasis drug, envudeucitinib, has shown industry-leading efficacy, with ~65% PASI 90 and >40% PASI 100 responses, positioning it as a leading oral psoriasis drug by 2030.
With a potential $2 billion annual sales as the TAM (Total Addressable Market) and considering the company's current market cap, the stock is expected to see a significant increase in value, making it a good time to average down and buy more.

Bearish· Sep 2

The company's phase 2 trial for its drug ESK-001 was a failure, leading to a significant decline in stock price.
The stock's strong reaction to the trial results was considered an overreaction, with some analysts pointing to the drug's continued potential in a specific subpopulation as a positive sign.
The stock's price target was lowered by Wells Fargo to $25 from $51, citing the stock's overdone move and little value for its psoriasis treatment, which has a high probability of success.

Generated by AI

Topics

Of the messages about ALMS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	68.94%	61.37%
Analysts	—	0%	15.11%	18.82%
Technical Analysis	—	0%	0.85%	6.5%
Earnings	—	100%	4.47%	0.83%
Macro	—	0%	10.64%	12.44%
Controversies	—	0%	0%	0.04%

Jan 6

Alumis Inc.'s lead candidate, envudeucitinib, reached the main goals in two Phase 3 trials for a skin disorder known as plaque psoriasis, with 74% of patients achieving Psoriasis Area and Severity Index (PASI) 75 and 59% achieving static Physician’s Global Assessment (sPGA) 0/1 at Week 16.
The Phase 3 ONWARD clinical program includes two parallel global, multi-center, randomized, double-blind, placebo and active-comparator-controlled 24-week trials, evaluating the efficacy and safety of envudeucitinib in adults with moderate-to-severe plaque psoriasis.
Alumis plans to present additional results from ONWARD1 and ONWARD2 at an upcoming medical meeting and to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration in the second half of this year.

Generated by AI

Community

Of the messages about ALMS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	16.13%	17.76%	15.53%
Newcomers	0%	83.87%	82.24%	84.47%

Regulars· Sep 1

The Phase 2b trial of Alumis' envudeucitinib for systemic lupus erythematosus (SLE) missed its primary and secondary endpoints, but the company is proceeding with plans for a Phase 3 trial for a subgroup of patients.
Alumis has announced topline results from the Envudeucitinib Phase 2b Trial, indicating progress towards an NDA submission, and the filing is significant as it pertains to the company's psoriasis NDA still set for Q4 2026.
The trial results showed robust responses in IFNGS-high patients, and Alumis' psoriasis drug is expected to be better than Otezla, with Takeda paying $4 billion for a similar drug in a crowded field.

Newcomers· Sep 10

Newcomers to $ALMS are focused on the recent insider buy of $10.7 million by Director Akkaraju Srinivas, which has increased his stake in the company by 16%.
Some newcomers are discussing the potential implications of this buy, with one user suggesting that executives buying with their own cash is a stronger insider signal.
Others are questioning the reasons behind the company's 57% drop, with one user asking if there was more nuance to missing the target in the Phase 2b trial.

Generated by AI

News

Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population

Alumis Inc. (NASDAQ:ALMS) reported that the 408-patient Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus did not meet its primary or secondary endpoints in the overall population. Envudeucitinib is an investigational oral inhibitor of tyrosine kinase 2, or TYK2. The primary endpoint was the British Isles Lupus Assessment Group-based Composite Lupus Assessment, […]

21d agoYahoo Finance

Also Discussed

Investors talking about ALMS also mention

#	Name	Attention
1	Zenas BioPharma, Inc.ZBIO	0%0
2	Monte Rosa Therapeutics, Inc.GLUE	0%0
3	Janux Therapeutics, Inc.JANX	0%0
4	Inhibrx Biosciences, Inc.INBX	0%0
5	Cullinan Therapeutics Inc.CGEM	0%new
6	VTYX - Ventyx Biosciences, Inc.	——
7	Mineralys Therapeutics, Inc.MLYS	0%+0
8	flyExclusive, Inc. Class A Common StockFLYX	0%0
9	Intelligent Bio Solutions Inc.INBS	0%0
10	EON Resources Inc. Class A Common StockEONR	0%0

Alumis Inc.

Healthcare
Biotechnology

Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for immune-mediated diseases. The company’s current pipeline centers on oral TYK2 inhibitors designed to address conditions such as plaque psoriasis and systemic lupus erythematosus, alongside a CNS-penetrant TYK2 program being studied for neuroinflammatory and neurodegenerative disorders. Alumis is also advancing lonigutamab, an antibody therapy aimed at thyroid eye disease, and additional discovery-stage programs built around its precision data analytics platform. The company works across immunology and inflammation, combining drug discovery, clinical development, and translational science to build treatments that may be used as monotherapy or in combination settings. Headquartered in South San Francisco, California, Alumis operates as a focused biotech platform in the autoimmune and immune dysfunction market.

Website

Location

280 East Grand Avenue

South San Francisco, CA, 94080

United States

Social

What share of all stock conversation is about ALMS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0.01% +0	0% +0

Sep 10

Alumis Inc. ($ALMS) director Akkaraju Srinivas made a significant open-market purchase of 986,721 shares worth $10.73M at $10.87 per share.
The purchase is considered a bullish signal, indicating the director's confidence in the company's future.
Alumis Inc. is preparing to submit a New Drug Application (NDA) for envudeucitinib, a treatment for psoriasis, in Q4 2026, which could be a catalyst for the stock.

Generated by AI

Sentiment

Of the messages about ALMS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +91.16	23.6% -37.88	74.07% -4.11
Bearish	—	0% -91.16	76.4% +37.88	25.93% +4.11

Bullish· Sep 2

$ALMS is expected to reach a price target of $37, according to Oppenheimer, making it a "no brainer" investment.
The company's psoriasis drug, envudeucitinib, has shown industry-leading efficacy, with ~65% PASI 90 and >40% PASI 100 responses, positioning it as a leading oral psoriasis drug by 2030.
With a potential $2 billion annual sales as the TAM (Total Addressable Market) and considering the company's current market cap, the stock is expected to see a significant increase in value, making it a good time to average down and buy more.

Bearish· Sep 2

The company's phase 2 trial for its drug ESK-001 was a failure, leading to a significant decline in stock price.
The stock's strong reaction to the trial results was considered an overreaction, with some analysts pointing to the drug's continued potential in a specific subpopulation as a positive sign.
The stock's price target was lowered by Wells Fargo to $25 from $51, citing the stock's overdone move and little value for its psoriasis treatment, which has a high probability of success.

Generated by AI

Topics

Of the messages about ALMS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	68.94%	61.37%
Analysts	—	0%	15.11%	18.82%
Technical Analysis	—	0%	0.85%	6.5%
Earnings	—	100%	4.47%	0.83%
Macro	—	0%	10.64%	12.44%
Controversies	—	0%	0%	0.04%

Jan 6

Alumis Inc.'s lead candidate, envudeucitinib, reached the main goals in two Phase 3 trials for a skin disorder known as plaque psoriasis, with 74% of patients achieving Psoriasis Area and Severity Index (PASI) 75 and 59% achieving static Physician’s Global Assessment (sPGA) 0/1 at Week 16.
The Phase 3 ONWARD clinical program includes two parallel global, multi-center, randomized, double-blind, placebo and active-comparator-controlled 24-week trials, evaluating the efficacy and safety of envudeucitinib in adults with moderate-to-severe plaque psoriasis.
Alumis plans to present additional results from ONWARD1 and ONWARD2 at an upcoming medical meeting and to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration in the second half of this year.

Generated by AI

Community

Of the messages about ALMS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	16.13%	17.76%	15.53%
Newcomers	0%	83.87%	82.24%	84.47%

Regulars· Sep 1

The Phase 2b trial of Alumis' envudeucitinib for systemic lupus erythematosus (SLE) missed its primary and secondary endpoints, but the company is proceeding with plans for a Phase 3 trial for a subgroup of patients.
Alumis has announced topline results from the Envudeucitinib Phase 2b Trial, indicating progress towards an NDA submission, and the filing is significant as it pertains to the company's psoriasis NDA still set for Q4 2026.
The trial results showed robust responses in IFNGS-high patients, and Alumis' psoriasis drug is expected to be better than Otezla, with Takeda paying $4 billion for a similar drug in a crowded field.

Newcomers· Sep 10

Newcomers to $ALMS are focused on the recent insider buy of $10.7 million by Director Akkaraju Srinivas, which has increased his stake in the company by 16%.
Some newcomers are discussing the potential implications of this buy, with one user suggesting that executives buying with their own cash is a stronger insider signal.
Others are questioning the reasons behind the company's 57% drop, with one user asking if there was more nuance to missing the target in the Phase 2b trial.

Generated by AI

Alumis

Social

Sep 10

Bullish· Sep 2

Bearish· Sep 2

Jan 6

Regulars· Sep 1

Newcomers· Sep 10

Cantor Fitzgerald reiterates Alumis stock rating on oral therapy outlook

Alumis at Morgan Stanley conference: psoriasis data lifts outlook

Why is Alumis stock rallying today?

Alumis at Cantor conference: psoriasis strength, lupus setback

Alumis director Akkaraju buys $5.8m, sells $1m of ALMS shares

Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population

Also Discussed

Alumis Inc.

Company Information

Location

Cantor Fitzgerald reiterates Alumis stock rating on oral therapy outlook

Alumis at Morgan Stanley conference: psoriasis data lifts outlook

Why is Alumis stock rallying today?

Alumis at Cantor conference: psoriasis strength, lupus setback

Alumis director Akkaraju buys $5.8m, sells $1m of ALMS shares

Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population

Also Discussed

Social

Sep 10

Bullish· Sep 2

Bearish· Sep 2

Jan 6

Regulars· Sep 1

Newcomers· Sep 10